Key result
Low dose fibrinolysis significantly reduced peak pulmonary artery pressure from 71.00 mmHg to 40.36 mmHg and improved right ventricular function in patients with sub-massive pulmonary thromboembolism.
Why the study?
The role of fibrinolysis in sub-massive pulmonary thromboembolism is not clear, with prior evidence showing improved hemodynamics and increased bleeding without mortality benefit compared to anticoagulation alone.
Observational (n=11)
Yes
Clinical study demonstrates improved right ventricular function in sub-massive pulmonary thromboembolism, suggesting advantages of half-dose thrombolysis.
Role of fibrinolysis in sub-massive pulmonary thromboembolism (PTE) is not clear. Improved hemodynamics with increased bleeding with fibrinolysis in patients with high risk sub massive PTE when compared to anticoagulation alone without mortality benefit is known.
No takes yet. Share an insight, caveat, or question.
Ramalingam et al. (2019) conducted an observational in High risk sub-massive pulmonary thromboembolism (n=11). Low dose fibrinolysis vs. Baseline (pre-thrombolysis) was evaluated on Peak Pulmonary artery pressure (mmHg) (p=<0.001). Low dose fibrinolysis significantly reduced peak pulmonary artery pressure from 71.00 mmHg to 40.36 mmHg and improved right ventricular function in patients with sub-massive pulmonary thromboembolism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: